

Remarks

Applicants have amended the specification to provide the priority claim. Claims 6-7 have been cancelled without prejudice. Claims 8-10 have been amended to remove multiple dependencies. New claim 16 has been added, which finds its support in the original claim 7. Claims 1-5 and 8-16 are pending after entry of this amendment. No new matter has been added by these amendments.

Applicants request a speedy Office Action on merit.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101172-1P US.

Respectfully submitted,
/Jianzhong SHEN, Reg.#48076/

Name: Jianzhong Shen
Dated: June 16, 2006
Reg. No.: 48,076
Phone No.: 302-886-8854
Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437